|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011860,
umls-concept:C0017628,
umls-concept:C0023779,
umls-concept:C0030705,
umls-concept:C0071097,
umls-concept:C0332307,
umls-concept:C0920563,
umls-concept:C1280500,
umls-concept:C1979963,
umls-concept:C2003903,
umls-concept:C2587213
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2004-7-23
|
|
pubmed:abstractText |
This study compared the effects of 52 weeks' treatment with pioglitazone, a thiazolidinedione that reduces insulin resistance, and glibenclamide, on insulin sensitivity, glycaemic control, and lipids in patients with Type 2 diabetes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0742-3071
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2004 Diabetes UK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
859-66
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15270789-Blood Glucose,
pubmed-meshheading:15270789-Diabetes Mellitus, Type 2,
pubmed-meshheading:15270789-Female,
pubmed-meshheading:15270789-Glyburide,
pubmed-meshheading:15270789-Humans,
pubmed-meshheading:15270789-Hypoglycemic Agents,
pubmed-meshheading:15270789-Insulin Resistance,
pubmed-meshheading:15270789-Lipids,
pubmed-meshheading:15270789-Male,
pubmed-meshheading:15270789-Middle Aged,
pubmed-meshheading:15270789-Thiazolidinediones
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
|
|
pubmed:affiliation |
Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
